Cargando…

On the Non-Redundant Roles of TDO2 and IDO1

Detalles Bibliográficos
Autor principal:	Puccetti, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202388/ https://www.ncbi.nlm.nih.gov/pubmed/25368621 http://dx.doi.org/10.3389/fimmu.2014.00522

Ejemplares similares

Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors
por: Platten, Michael, et al.
Publicado: (2015)

Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO
por: Kim, Minah, et al.
Publicado: (2021)

Role of IDO and TDO in Cancers and Related Diseases and the Therapeutic Implications
por: Ye, Zixiang, et al.
Publicado: (2019)

Identification and optimisation of next generation inhibitors of IDO1 and TDO
por: Wise, Alan, et al.
Publicado: (2015)

The Coevolution of IDO1 and AhR in the Emergence of Regulatory T-Cells in Mammals
por: Grohmann, Ursula, et al.
Publicado: (2015)

Induction of TDO2 and IDO2 in Liver by High-Fat Feeding in Mice: Discrepancies with Human Obesity
por: Poulain-Godefroy, Odile, et al.
Publicado: (2013)

Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses
por: Merlo, Lauren M. F., et al.
Publicado: (2020)

Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer
por: Wu, Chunjing, et al.
Publicado: (2023)

Impact of IDO1 and IDO2 on the B Cell Immune Response
por: Merlo, Lauren M. F., et al.
Publicado: (2022)

Genetic Polymorphisms Affecting IDO1 or IDO2 Activity Differently Associate With Aspergillosis in Humans
por: Napolioni, Valerio, et al.
Publicado: (2019)

Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn–AhR–AQP4 signaling pathway
por: Du, Lisha, et al.
Publicado: (2020)

Indoximod opposes the immunosuppressive effects mediated by IDO and TDO via modulation of AhR function and activation of mTORC1
por: Brincks, Erik L., et al.
Publicado: (2020)

Correction: Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn–AhR–AQP4 signaling pathway
por: Du, Lisha, et al.
Publicado: (2021)

IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era
por: Chen, Xiangli, et al.
Publicado: (2020)

Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening
por: Sari, Suat, et al.
Publicado: (2019)

Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBPβ
por: Kudo, Takumi, et al.
Publicado: (2020)

AhR-Mediated, Non-Genomic Modulation of IDO1 Function
por: Pallotta, Maria Teresa, et al.
Publicado: (2014)

Sodium Tanshinone IIA Sulfonate as a Potent IDO1/TDO2 Dual Inhibitor Enhances Anti-PD1 Therapy for Colorectal Cancer in Mice
por: Zhang, Rongjie, et al.
Publicado: (2022)

IDO2 in Immunomodulation and Autoimmune Disease
por: Prendergast, George C., et al.
Publicado: (2014)

Preclinical PK investigation of a novel IDO1/TDO dual inhibitor—SHR9146 in mouse plasma and tissues by LC-MS/MS
por: Xiao, Mei, et al.
Publicado: (2023)

The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1
por: Panfili, Eleonora, et al.
Publicado: (2023)

Immunological Relevance of the Coevolution of IDO1 and AHR
por: Jaronen, Merja, et al.
Publicado: (2014)

Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines Expressing Either Murine or Human IDO1 or TDO2
por: Tijono, Sofian M, et al.
Publicado: (2022)

Current Challenges for IDO2 as Target in Cancer Immunotherapy
por: Mondanelli, Giada, et al.
Publicado: (2021)

IDO-GCN2 and autophagy in inflammation
por: McGaha, Tracy L.
Publicado: (2015)

TDO Promotes Hepatocellular Carcinoma Progression
por: Li, Shanbao, et al.
Publicado: (2020)

IDO Targeting in Sarcoma: Biological and Clinical Implications
por: Nafia, Imane, et al.
Publicado: (2020)

IDO and Kynurenine Metabolites in Peripheral and CNS Disorders
por: Huang, Yi-Shu, et al.
Publicado: (2020)

Evaluating the role of IDO1 macrophages in immunotherapy using scRNA-seq and bulk-seq in colorectal cancer
por: Liu, Xingwu, et al.
Publicado: (2022)

New Insights into IDO Biology in Bacterial and Viral Infections
por: Schmidt, Susanne V., et al.
Publicado: (2014)

Targeting Tregs in Malignant Brain Cancer: Overcoming IDO
por: Wainwright, Derek A., et al.
Publicado: (2013)

IDO Expression in Cancer: Different Compartment, Different Functionality?
por: Meireson, Annabel, et al.
Publicado: (2020)

Tryptophan Feeding of the IDO1-AhR Axis in Host–Microbial Symbiosis
por: Zelante, Teresa, et al.
Publicado: (2014)

Tolerogenic IDO(+) Dendritic Cells Are Induced by PD-1-Expressing Mast Cells
por: Rodrigues, Cecilia Pessoa, et al.
Publicado: (2016)

Comprehensive Analysis of the Expressionand Prognosis for TDO2 in Breast Cancer
por: Liu, Qiang, et al.
Publicado: (2020)

Clinicopathologic features of TDO2 overexpression in renal cell carcinoma
por: Pham, Quoc Thang, et al.
Publicado: (2021)

Pharmacological validation of TDO as a target for Parkinson’s disease
por: Perez‐Pardo, Paula, et al.
Publicado: (2021)

Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies
por: Zhai, Lijie, et al.
Publicado: (2020)

Pancancer Analysis of Revealed TDO2 as a Biomarker of Prognosis and Immunotherapy
por: Cui, Jing, et al.
Publicado: (2022)

IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation
por: Amobi-McCloud, Adaobi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rfhbl5lgfjpvoukq42fh3t1tpp